Department of Psychiatry, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.
Aust N Z J Psychiatry. 2021 Apr;55(4):366-380. doi: 10.1177/0004867420952543. Epub 2020 Sep 8.
The primary indication for electroconvulsive therapy is medication-resistant major depression. There is some evidence that combining electroconvulsive therapy with an antidepressant, instead of electroconvulsive therapy monotherapy, might improve remission rates. However, data on this topic have not been systematically studied. We undertook a systematic review and meta-analysis to determine the effectiveness of an adjuvant antidepressant during electroconvulsive therapy for major depression.
Embase, Medline Ovid, Web of Science, Cochrane Central, PsychINFO Ovid and Google Scholar were searched up to January 2019. Randomized controlled trials and cohort studies reporting on the influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy for major depression were included. Authors independently screened records, extracted data and assessed study quality. We reported this systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Nine studies were included in the meta-analysis. The meta-analysis revealed a significant advantage of adjuvant antidepressants versus placebo. The overall effect size per category of antidepressant was as follows: tricyclic antidepressants: Hedges' 0.32 (95% confidence interval: [0.14, 0.51]) ( = 6) with low heterogeneity (: 4%, = 0.39); selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitors: Hedges' 0.27 (95% confidence interval: [0.03, 0.52]) ( = 2) with a lack of heterogeneity (: 0%, = 0.89); and monoamine oxidase inhibitors: Hedges' 0.35 (95% confidence interval: [-0.07, 0.77]) with moderate heterogeneity (: 43%, = 0.17) ( = 3).
An adjuvant antidepressant enhances the efficacy of electroconvulsive therapy for major depression. Tricyclic antidepressants, selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitors and monoamine oxidase inhibitors showed the same effect size. However, the effect sizes of tricyclic antidepressants and monoamine oxidase inhibitors are most likely underestimated, due to insufficient doses in most of the included studies. We recommend the routine use of an adequately dosed antidepressant during electroconvulsive therapy for major depression.
电抽搐治疗的主要适应证是药物难治性重度抑郁症。有一些证据表明,将电抽搐治疗与抗抑郁药联合使用,而不是电抽搐治疗单一疗法,可能会提高缓解率。然而,关于这个主题的数据尚未进行系统研究。我们进行了一项系统回顾和荟萃分析,以确定电抽搐治疗重度抑郁症时辅助使用抗抑郁药的效果。
检索了 Embase、Medline Ovid、Web of Science、Cochrane Central、PsychINFO Ovid 和 Google Scholar,截至 2019 年 1 月。纳入了报告辅助使用抗抑郁药对电抽搐治疗重度抑郁症疗效影响的随机对照试验和队列研究。作者独立筛选记录、提取数据并评估研究质量。我们根据系统评价和荟萃分析的首选报告项目报告了这项系统评价和荟萃分析。
有 9 项研究纳入荟萃分析。荟萃分析显示,辅助使用抗抑郁药优于安慰剂。每类抗抑郁药的总体效果大小如下:三环类抗抑郁药:Hedges' 0.32(95%置信区间:[0.14,0.51])( = 6),异质性低(4%, = 0.39);选择性 5-羟色胺再摄取抑制剂/5-羟色胺去甲肾上腺素再摄取抑制剂:Hedges' 0.27(95%置信区间:[0.03,0.52])( = 2),异质性缺乏(0%, = 0.89);和单胺氧化酶抑制剂:Hedges' 0.35(95%置信区间:[-0.07,0.77]),异质性中度(43%, = 0.17)( = 3)。
辅助使用抗抑郁药可增强电抽搐治疗重度抑郁症的疗效。三环类抗抑郁药、选择性 5-羟色胺再摄取抑制剂/5-羟色胺去甲肾上腺素再摄取抑制剂和单胺氧化酶抑制剂具有相同的效果大小。然而,由于大多数纳入研究中的剂量不足,三环类抗抑郁药和单胺氧化酶抑制剂的效果大小很可能被低估了。我们建议在电抽搐治疗重度抑郁症时常规使用适当剂量的抗抑郁药。